Development of a Novel Acoustic Resuscitation Monitor

新型声学复苏监测仪的开发

• 批准号: 7088869
• 负责人: JOHN Milton SEWELL
• 金额: $ 14.56万
• 依托单位: ACTIVE SIGNAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7088869
• 关键词: biomedical equipment development; blood circulation; blood pressure; carotid artery; clinical biomedical equipment; clinical research; critical care; hemorrhagic shock; human subject; lactates; noninvasive diagnosis; oxygen therapy; patient monitoring device; portable biomedical equipment; resuscitation; trauma; vasoconstriction

DESCRIPTION (provided by applicant): Currently almost half of all trauma mortality is directly or indirectly attributable to hemorrhagic shock, accounting for more than 50,000 deaths yearly in the U.S. and hundreds of billions of dollars in economic costs. Active Signal Technologies proposes to develop an Acoustic Resuscitation Monitor (ARM) for enabling non-invasive assessment of systemic perfusion in real time, with the ultimate goal of developing a device that can continuously monitor shock and resuscitation in the field. As no such device exists and current perfusion tests have significant lag time, ARM can significantly improve patient outcome and lower costs both for in-hospital (Phase I) and field (Phase II) settings. The ARM technology is based on Active Signal's Brain Acoustic Monitor (BAM) - demonstrated effectively in brain perfusion studies on more than 500 trauma and 100 stroke patients. In Phase I Active Signal with the University of Maryland Shock Trauma Center will conduct feasibility tests on approximately 100 patients with 5 data collection times. Specific aims are to determine the relationship between vasoconstriction as indicated by ARM using pulse-waveform characteristics and systemic perfusion measured by current clinical metrics, and to reconfigure the BAM to monitor vasoconstriction at 3 arterial tree levels.

描述(申请人提供)：目前几乎一半的创伤死亡直接或间接归因于失血性休克，在美国每年造成超过50,000人死亡，造成数千亿美元的经济损失。主动信号技术公司建议开发一种声学复苏监测器(ARM)，以实现对系统血流的实时非侵入性评估，最终目标是开发一种可以在现场连续监测休克和复苏的设备。由于没有这样的设备，而且目前的灌流测试有明显的滞后时间，ARM可以显著改善患者的预后，并降低住院(I期)和现场(II期)设置的成本。ARM技术基于Active Signal的脑声监测器(BAM)--在对500多名创伤和100名中风患者进行的脑血流灌注研究中证明了这一点。在第一阶段，马里兰大学休克创伤中心的Active Signal将对大约100名患者进行5次数据收集的可行性测试。具体目的是确定ARM使用脉搏波形特征指示的血管收缩与当前临床指标测量的全身血流灌注之间的关系，并重新配置BAM以在3个动脉树水平监测血管收缩。